Parkinson's disease (PD) is a progressive neurologic motor disorder. Currently, levodopa/carbidopa is the standard mode of therapy for PD; however, it does not prevent progression of the disease. Selegiline (also known as deprenyl), is a selective irreversible monoamine oxidase type B inhibitor virtually devoid of the tyramine reaction at the recommended dosage of 10 mg/d. It is approved by the Food and Drug Administration for the adjunctive use in the management of patients with PD who are receiving levodopa/carbidopa and exhibit a “wearing off' effect of levodopa. Numerous clinical trials have been conducted evaluating selegiline's role in the treatment of PD. Preliminary evidence from the DATATOP trial suggests that selegiline may slow the progression of PD when used as initial therapy. However, final results of this trial and additional long-term controlled trials comparing selegiline to levodopa and placebo groups are necessary to further clarify selegiline's role in the treatment of PD.
Get full access to this article
View all access options for this article.
References
1.
FlahertyJF. Parkinson's disease. In: YoungLYKoda-KimbleMA, eds. Applied therapeutics: The clinical use of drugs. 4th ed. Vancouver, WA: Applied Therapeutics, 1988: 1349–67.
2.
ElizanTSYahrMDMorosDA, Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch Neurol1989; 46: 1275–9.
3.
BirkmayerWRiedererPAmbroziL, Implications of combined treatment with “Madopar” and l-deprenyl in Parkinson's disease. Lancet1977; 2: 439–43.
4.
RinneUKShrtolaTSonninenV. L-deprenyl treatment of on-off phenomena in Parkinson's disease. J Neural Transm1978; 43: 253–62.
5.
StreiflerMVardiJBorensteinN, Beta-type monoamine oxidase (MAO) inhibitors in long-term levo-dopa-treated parkinsonism: A combined clinical trial with l-deprenyl. Curr Ther Res1980; 27: 643–8.
6.
StreiflerMRabeyMJ. Long-term effects of l-deprenyl in chronic levodopa treated parkinsonian patients. J Neural TransmSuppl1983; 19: 265–72.
7.
RinneUK. Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol ScandSuppl1983; 95: 107–11.
8.
GerstenbrandFRansmayrGPoeweW. Deprenyl (selegiline) in combination treatment of Parkinson's disease. Acta Neurol ScandSuppl1983; 95: 123–6.
9.
LiebermanANGopinathanGNeophytidesA, Deprenyl in the treatment of Parkinson's disease: A specific type b monoamine oxidase inhibitor. NY State J Med1983; 84: 13–6.
10.
RuggieriSDenaroAMecoG, Multicenter trial of l-deprenyl in Parkinson's disease. Ital J Neurol Sci1986; 7: 133–7.
11.
CsandaETarczyM. Selegiline in the early and late phases of Parkinson's disease. J Neural TransmSuppl1987; 25: 105–13.
12.
UlmGFornadiF. R-(-)-deprenyl in the treatment of end-of-dose akinesia. J Neural TransmSuppl1987; 25: 163–72.
13.
ElizanTSYahrMDMorosDA, Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type-B monoamine oxidase inhibitor in 200 patients. Arch Neurol1989; 46: 1280–3.
14.
HoehnNMYahrMD. Parkinsonism: Onset, progression and mortality. Neurology1967; 17: 427–42.
15.
EislerTTeravainenHNelsonR, Deprenyl in Parkinson's disease. Neurology1981; 31: 19–23.
16.
LeesAJShawKMKohoutLJ, Deprenyl in Parkinson's disease. Lancet1977; 2: 791–5.
17.
SternGMLeesAJSandlerM. Recent observations on the clinical pharmacology of (-)deprenyl. J Neural Transm1978; 43: 245–51.
18.
SchachterMMarsdenCDParkesJD, Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry1980; 43: 1016–21.
19.
CelanoPGoldsteinL. The “on-off” phenomena in Parkinson's disease–treatment and theoretical considerations. Mt Sinai J Med1980; 47: 80–4.
20.
PresthusJHajbaA. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Acta Neurol ScandSuppl1983; 95: 127–33.
21.
BrodersenPPhilbertAGulliksenG, The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand1985; 71: 494–7.
22.
PresthusJBerstadJLienK. Selegiline (l-deprenyl) and low-dose levodopa treatment of Parkinson's disease. Acta Neurol Scand1987; 76: 200–3.
23.
FischerPABaasH. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural TransmSuppl1987; 25: 137–47.
24.
GolbeLIDuvoisinRC. Double-blind trial of R-(-)-deprenyl for the “on-off” effect complicating Parkinson's disease. J Neurol TransmSuppl1987; 25: 123–9.
25.
PrzuntekHKuhnW. The effect of R-(-)-deprenyl in de novo parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural TransmSuppl1987; 25: 97–104.
26.
LiebermanANGopinathanGNeophytidesA, Deprenyl versus placebo in Parkinson disease: A double-blind study. NY State J Med1987; 87: 646–9.
27.
GolbeLILiebermanANMuenterMD, Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol1988; 11: 45–55.
28.
RascolOMontastrucJLSenardJM, Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: A double-blind cross-over placebo-controlled trial. Neurology1988; 38: 1387–91.
29.
GolbeLI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology1989; 39: 1109–11.
30.
TetrudJWLangstonJW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science1989; 245: 519–22.
31.
Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol1989; 46: 1052–60.
32.
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med1989; 321: 1364–71.
33.
TetrudJWLangstonJW. R-(-)-deprenyl as a possible protective agent in Parkinson's disease. J Neural TransmSuppl1987; 25: 69–79.
